Skip to main content

Advertisement

Table 1 Patient demographic and clinical characteristics at index

From: Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records

Characteristics Lurasidone (N = 439)
Age (years), mean (SD) 42.2 (13.5)
Female, N (%) 306 (69.7%)
Follow-up duration (days), mean (SD) 225.1 (124.6)
Diagnosis of schizophrenia or bipolar disorder, N (%)
 Schizophrenia spectrum diagnosis 83 (18.9%)
 Bipolar disorder diagnosis 206 (46.9%)
 Other/unknown diagnosisa 150 (34.2%)
Prior use of any second-generation antipsychotics N (%) 201 (45.8%)
Prior use of second-generation antipsychotics associated with medium or higher risk for weight gainb 119 (27.1%)
Prior use of any first-generation antipsychotic, N (%) 62 (14.1%)
Prior use of other medications, N (%)
 Antidepressants 246 (56.0%)
 Diuretics 90 (20.5%)
Comorbidities, N (%)
 Depression 196 (44.6%)
 Substance abuse 166 (37.8%)
 Hypertension 158 (36.0%)
 Hyperlipidemia 155 (35.3%)
 Diabetes 89 (20.3%)
 Chronic obstructive pulmonary disease 85 (19.4%)
Charlson Comorbidity Index Score, mean (SD) 0.8 (1.3)
Weightc and BMI classificationd
 Weight (kg), mean (SD) 93.9 (25.4)
 Underweight, N (%) 4 (0.9%)
 Normal, N (%) 70 (15.9%)
 Overweight, N (%) 89 (20.3%)
 Obese, N (%) 276 (62.9%)
  1. aAs lurasidone would not be prescribed for any other condition except schizophrenia and bipolar, and the lack of a diagnosis in administrative data does not indicate the lack of the disorder, the data from these patients was deemed acceptable to use in the analysis
  2. bSecond-generation antipsychotics associated with medium or higher risk of weight gain included clozapine, olanzapine, quetiapine, and risperidone
  3. cWeight was the most recent weight observation at index (i.e., weight observation closest to and before index date)
  4. dBMI classification based on the closest BMI reading prior to the index date. Underweight, BMI < 18.5 kg/m2; normal weight, BMI ≥ 18.5 and < 25.0 kg/m2; overweight, BMI ≥ 25.0 and < 30 kg/m2; obese, BMI ≥ 30 kg/m2